每经AI快讯，1月27日，恒瑞医药(600276.SH)公告称，公司子公司山东盛迪医药的HRS-5346片被国家 药品监督管理局药品审评中心纳入突破性治疗品种名单。该药物用于治疗脂蛋白（a）水平的升高，目 前国内外尚无同类产品获批上市。截至目前，HRS-5346片相关项目累计研发投入约为7,630万元。药品 研发存在技术、审批、政策等多方面因素的影响，审评政策及未来药品市场竞争形势等存在不确定性风 险。 （文章来源：每日经济新闻） ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临2026-013 江苏恒瑞医药股份有限公司 申请日期：2025年12月16日 拟定适应症（或功能主治）：用于治疗脂蛋白（a）水平的升高。 理由及依据：经审核，本申请符合《药品注册管理办法》和《国家药监局关 于发布＜突破性治疗药物审评工作程序（试行）＞等三个文件的公告》（2020年 第82号）有关要求，同意纳入突破性治疗药物程序。 关于药物纳入突破性治疗品种名单的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日,江苏恒瑞医药股份有限公司（以下简称"公司"）子公司山东盛迪医药 有限公司的HRS-5346片被国家药品监督管理局药品审评中心（以下简称"药审中 心"）纳入突破性治疗品种名单。现将相关情况公告如下： 一、药物的基本情况 药物名称：HRS-5346片 受理号：CXHL2400233 药物类型：化学药品 注册分类：1类 二、药物的其他相关情况 脂蛋白(a)[Lp(a)]水平升高是全球最普遍的单基因脂质疾病，是脂蛋白紊乱 的典型表现之一。中国成年人的Lp(a)水平 ...

恒瑞医药（600276）(01276)发布公告，于2026年1月27日该公司斥资人民币1003.86万元回购17.5万股A 股，回购价格为每股人民币57.20-57.48元。 ...

MACD金叉信号形成，这些股涨势不错！ 恒瑞医药1月27日公告，公司于2025年8月20日召开第九 届董事会第十八次会议审议通过了《关于以集 中竞价交易方式回购公司A股股份 方案的议案》,同意公司使用自有资金,以集中竞价交易方式回购公司 股份用于实 施A股员工持股计划｡回购价格不超过90.85元/股（含）,回购资金总额不低于10亿元且不超 过20亿元｡回购期限为自董事会审议通过回购股份 方案之日起12个月以内｡截至2026年1月27日，公司累 计回购907.37万股，占公司总股本的0.14%，回购价格区间为57.2元/股至70元/股，累计使用资金6.05亿 元（不含交易费用）。 ...

恒瑞医药公告，子公司山东盛迪医药有限公司的HRS-5346片被国家药品监督管理局药品审评中心纳入 突破性治疗品种名单。HRS-5346是一种Lp（a）口服小分子抑制剂，拟用于治疗脂蛋白（a）水平的升 高。目前国内外尚无同类产品获批上市。 ...

智通财经APP讯，恒瑞医药(01276)发布公告，于2026年1月27日该公司斥资人民币1003.86万元回购17.5 万股A股，回购价格为每股人民币57.20-57.48元。 ...

格隆汇1月27日丨恒瑞医药(01276.HK)发布公告，2026年1月27日耗资人民币1003.9万元回购17.5万股A 股，回购价格每股57.2-57.48元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2026年1月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | ...

Core Viewpoint - The report highlights the current AH premium rates of various stocks, indicating significant disparities between H-shares and A-shares, with some stocks showing extremely high premiums while others exhibit negative premiums. Group 1: Top AH Premium Rates - Northeast Electric (00042) has the highest AH premium rate at 800.00% [1] - Zhejiang Shibao (01057) follows with a premium rate of 351.95% [1] - Beijing Machinery (00187) ranks third with a premium rate of 269.91% [1] - The top ten stocks with high premium rates include companies like Hongye Futures (03678) and Sinopec Oilfield Services (01033) with premium rates of 264.44% and 263.64% respectively [2] Group 2: Bottom AH Premium Rates - Contemporary Amperex Technology (03750) has the lowest AH premium rate at -12.95% [3] - China Merchants Bank (03968) and Heng Rui Medicine (01276) follow with rates of -3.26% and -2.69% respectively [3] - Other companies in the bottom tier include Wu Chai Power (02338) and Midea Group (00300) with positive but low premiums of 7.63% and 8.11% [3] Group 3: Top Deviation Values - Andeli Juice (02218) has the highest deviation value at 28.13% [4] - Goldwind Technology (02208) and Junshi Biosciences (01877) follow with deviation values of 23.37% and 16.76% respectively [4] - Other notable companies include Beijing Machinery (00187) with a deviation value of 12.63% [4] Group 4: Bottom Deviation Values - Zhejiang Shibao (01057) has the lowest deviation value at -39.21% [5] - Northeast Electric (00042) and Yangtze Optical Fibre and Cable (06869) follow with deviation values of -38.76% and -35.09% respectively [5] - Other companies with negative deviation values include Nanhua Futures (02691) and Chenming Paper (01812) [5]

Company News - China Power (02380.HK) expects a total consolidated electricity sales volume of 10.73105 million MWh by December 2025, a decrease of 2.31% year-on-year; the total annual electricity sales volume is approximately 126 million MWh, down 1.27% year-on-year [2] - Harbin Electric (01133.HK) anticipates a net profit attributable to shareholders of approximately RMB 2.65 billion for the fiscal year 2025, compared to RMB 1.686 billion in the previous year, mainly due to increased operating revenue and improved product profitability [2] - Singularity Guofeng (01280.HK) has entered into a GPU distribution cooperation agreement with Muxi Co., aiming to enter the domestic AI computing power market [2] - Dongyang Sunshine Pharmaceutical (06887.HK) has signed a strategic cooperation agreement with Shenzhen Jingtai to establish a joint venture for building an AI-driven drug research and development platform [2] - Weisheng Pharmaceutical-B (02561.HK) has received approval from the National Medical Products Administration for the marketing authorization application of injectable Long Pei growth hormone [2] - Kintor Pharmaceutical-B (02171.HK) issued a profit warning, expecting a net loss for 2025 to be reduced to no more than approximately RMB 120 million [2] - Zhaoke Ophthalmology-B (06622.HK) is advancing the commercialization process of BRIMOCHOL PF for treating presbyopia in Singapore and Vietnam through partnerships with AFT and Qianshou [2] Additional Company Developments - Heng Rui Medicine (01276.HK) has received a clinical trial approval notice for SHR-1049 injection [3] - Baolong Real Estate (01238.HK) has had its bond restructuring plan approved by the relevant bondholders' meeting [3] Strategic Partnerships - Yabo Technology Holdings (08279.HK) has entered into a technical service agreement with Hong Kong Gold Exchange Limited [4] - Future Data Group (08229.HK) has signed a strategic cooperation framework agreement with Linghe Culture [4] - Howey Group (00501.HK) plans to invest up to USD 50 million to subscribe for shares in Aixin Yuanzhi's initial public offering [4] Buyback Activities - Xiaomi Group-W (01810.HK) repurchased 3.9872 million shares for HKD 140 million, with a repurchase price ranging from HKD 35.04 to HKD 35.22 [5] - China Metallurgical Group (01618.HK) repurchased 9.011 million shares for HKD 16.9299 million, with a repurchase price of HKD 1.87 to HKD 1.88 [5] - Geely Automobile (00175.HK) repurchased 4.401 million shares for HKD 72.952 million, with a repurchase price ranging from HKD 16.43 to HKD 16.65 [6] - Reshape Energy (02570.HK) completed the placement of a total of 4.536 million placement shares, raising approximately HKD 258 million [6] - Kintor Pharmaceutical-B (09939.HK) saw an increase of 4.7 million shares by Chairman Tong Youzhi [6]